- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Prenetics divests 3PL distribution business in all-stock deal valued at up to $13M | 2 | Seeking Alpha | ||
| Mo | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 31.12.25 | David Beckham's Prenetics halts $1B Bitcoin plan to focus on IM8 health brand | 1 | iNVEZZ.com | ||
| 30.12.25 | Prenetics halts Bitcoin purchases to focus on consumer health brand, IM8 | 2 | Seeking Alpha | ||
| 30.12.25 | Prenetics Global Limited: Prenetics Announces Update to Capital Allocation Strategy; Ceases Bitcoin Purchases to Focus on IM8 | 135 | GlobeNewswire (Europe) | Company's Capital and Strategic Focus Now Exclusively Focused on IM8 IM8 FY 2026 Revenue Projected to Reach $180 - $200 Million CHARLOTTE, N.C., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Prenetics Global... ► Artikel lesen | |
| 23.12.25 | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| PRENETICS GLOBAL Aktie jetzt für 0€ handeln | |||||
| 23.12.25 | Prenetics Global Limited: Prenetics Enters Into Warrant Exchange Agreements With Warrant Holders, Strengthening Capital Structure | 247 | GlobeNewswire (Europe) | CHARLOTTE, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and... ► Artikel lesen | |
| 11.12.25 | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 24.11.25 | Prenetics executives purchase $1.4 million in company stock | 1 | Investing.com | ||
| 24.11.25 | Prenetics executives buy $1.45M in company stock | 2 | Seeking Alpha | ||
| 24.11.25 | Prenetics-Management investiert 1,45 Millionen US-Dollar in eigene Aktien | 1 | Investing.com Deutsch | ||
| 24.11.25 | Prenetics Global Limited: Prenetics Executives Announce Open Market Share Purchases Totaling Approx. $1.45 Million | 2 | GlobeNewswire (USA) | ||
| 17.11.25 | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.11.25 | Prenetics Global Limited: Cantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price Target of $31 Following Strong IM8 Growth | 375 | GlobeNewswire (Europe) | IM8's Strong Unit Economics-60% Margins and 3.9-Month Payback-Central to Cantor's Bullish Outlook Cantor Notes PRE's ~$120M Liquidity and 387 BTC Treasury as Strengthening the Company's Financial... ► Artikel lesen | |
| 12.11.25 | Cantor Fitzgerald lowers Prenetics stock price target to $31 on Q3 results | 2 | Investing.com | ||
| 10.11.25 | Prenetics Global GAAP EPS of -$0.53, revenue of $23.6M | 3 | Seeking Alpha | ||
| 10.11.25 | Prenetics Global Limited: Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR by December 2025, Fastest Supplement Brand Growth in Industry History | 178 | GlobeNewswire (Europe) | Total Revenue Surges 568% YoY to $23.6 million; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 - $200M FY 2026 Revenue, $25M... ► Artikel lesen | |
| 10.11.25 | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 07.11.25 | Prenetics Global's Earnings: A Preview | 1 | Benzinga.com | ||
| 04.11.25 | Prenetics' IM8 achieves record $9M in revenue for October | 3 | Seeking Alpha |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CANSINO BIOLOGICS | 3,720 | -10,01 % | CANSINOBIO (06185): VOLUNTARY ANNOUNCEMENT - PCV24 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA | ||
| SINO BIOPHARM | 0,720 | +0,19 % | SINO BIOPHARM (01177): VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE PHASE III CLINICAL TRIAL OF TDI01 "ROCK2 INHIBITOR" ... | ||
| GENSCRIPT BIOTECH | 1,415 | -3,35 % | GenScript USA: 'Scripting Possibilities' in Biotechnology: Global Innovators Converge in San Francisco for GenScript's 5th Annual Biotech Forum During JPM Week | PISCATAWAY, N.J., Jan. 6, 2026 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, is proud to announce its 5th Annual Biotech... ► Artikel lesen | |
| QUANTUM-SI | 1,280 | 0,00 % | Quantum-Si Inc - 8-K, Current Report | ||
| INNOVENT BIOLOGICS | 9,300 | -1,06 % | Daiwa Names INNOVENT BIO as Top Pick Alongside HENGRUI PHARMA w/TP Lifted to HKD112 | ||
| SCILEX | 13,210 | -1,56 % | Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel | ||
| AKESO | 12,200 | -7,58 % | Daiwa Downgrades AKESO to Hold on Lack of ST Catalysts, Elevates TP to $116 | ||
| ORIGIN AGRITECH | 0,975 | +7,14 % | Origin Agritech Limited: Origin Agritech Obtains New Licenses for Crop Seed Production and GMO Business Operations | Strategic Restructuring Positions Company to Strengthen Market Presence with Expanded Operational Capabilities
BEIJING, Oct. 24, 2025 /PRNewswire/ -- Origin Agritech... ► Artikel lesen | |
| ALUMIS | 16,250 | 0,00 % | Alumis Stock Hits Record High on Psoriasis Drug Trial Results | ||
| APOGEE THERAPEUTICS | 78,25 | +0,95 % | Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and ... | Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,120 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| ARCELLX | 62,06 | 0,00 % | Arcellx, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| QIAGEN | 39,985 | +2,87 % | QIAGEN NV - Stabilität als strategische Zone | ||
| RECURSION PHARMACEUTICALS | 4,550 | 0,00 % | JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline | ||
| BEAM THERAPEUTICS | 28,340 | 0,00 % | Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock? |
PRENETICS GLOBAL LIMITED gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,77 % bei einem Aktienkurs von 16,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRENETICS GLOBAL LIMITED finden Sie auf Wallstreet Online.